Innovent’s IBI306 Meets its Primary Endpoint in P-III CREDIT-2 Study for Heterozygous Familial Hypercholesterolemia

August 12, 2021 Auto Bot Clinical Trials 0

Shots:

  • The P-III CREDIT-2 study evaluates the efficacy and safety of IBI306 vs PBO in 148 Chinese patients with HeFH, prior treated with statins and ezetimibe. The study provides high-quality clinical evidence for patients with the same indication
  • The study met its 1EPs i.e., reduction in the LDL-C levels @12wks. of continuous treatment & demonstrated a safety profile similar to the reported safety profiles of other marketed PCSK-9 inhibitors
  • IBI306 is an lgG2 mAb that binds to PCSK-9. Additionally, P-I & IIa study for IBI306 demonstrated good efficacy with a favorable safety profile to treat patients with hypercholesterolemia

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Innovent

The post Innovent’s IBI306 Meets its Primary Endpoint in P-III CREDIT-2 Study for Heterozygous Familial Hypercholesterolemia first appeared on PharmaShots.